Vital Transformation leads a new consortium investigating the relationship between public funding and private investment into new innovative therapies and the supporting system of IP.

This project will develop original research that identifies the success factors that create high-value EU biotech companies and the role of IP in creating an ecosystem where investors are willing to lose everything 92% of the time, in order to fund the 8% of medical breakthroughs that occasionally succeed.

Supported by: